利伐沙班用于下肢旁路术后有症状外周动脉疾病患者:静脉与人工血管移植物
VOYAGER PAD试验事后分析纳入2185例下肢旁路手术患者,比较利伐沙班2.5 mg每日两次与安慰剂在抗血小板治疗基础上的疗效与安全性。人工血管组非计划下肢血运重建和急性肢体缺血风险显著高于静脉血管组;利伐沙班降低主要复合终点,静脉组HR 0.66、人工血管组HR 0.87,交互作用P=0.254。
要点
- 人工血管旁路患者非计划下肢血运重建风险约为静脉血管的2.53倍,急性肢体缺血风险约为3.07倍。
- 利伐沙班2.5 mg每日两次降低旁路术后主要复合终点(HR 0.78),静脉与人工血管获益一致。
- 旁路术后TIMI大出血利伐沙班组5例 vs 安慰剂组9例(HR 0.55),未达统计学显著。
核心结论
- 人工血管旁路与静脉血管相比,校正患者和解剖因素后主要不良肢体事件发生率显著更高。
- 在阿司匹林或双联抗血小板治疗基础上加用利伐沙班2.5 mg每日两次显著降低该风险,出血风险增加,但无论移植物类型如何,旁路手术患者获益风险比有利。
- 作者认为有症状外周动脉疾病患者下肢旁路术后应考虑使用利伐沙班,以减少心、肢体和脑的缺血并发症。
研究设计与样本
- VOYAGER PAD试验的事后分析,患者接受外科和血管内腹股沟下下肢血运重建后随机分配至利伐沙班2.5 mg每日两次或安慰剂,背景抗血小板治疗(阿司匹林100 mg全部使用,氯吡格雷部分由治疗医生决定),中位随访28个月。
- 6564例随机患者中2185例(33%)接受外科下肢血运重建,其中1448例(66%)行外科旁路,773例(53%)使用人工血管,646例(45%)使用静脉血管。
- 主要终点为急性肢体缺血、血管原因大截肢、心肌梗死、缺血性卒中及心血管死亡的复合终点;主要安全性结局为采用TIMI量表定义的大出血。
主要发现
- 安慰剂组中,人工血管较静脉血管的非计划下肢血运重建风险校正HR为2.53(95%CI 1.65-3.90,P<.001),急性肢体缺血风险校正HR为3.07(95%CI 1.84-5.11,P<.001)。
- 旁路手术患者中利伐沙班降低主要终点(HR 0.78,95%CI 0.62-0.98),静脉血管组HR 0.66(95%CI 0.49-0.96),人工血管组HR 0.87(95%CI 0.66-1.15),交互作用P=0.254。
- 旁路手术患者TIMI大出血利伐沙班组5例 vs 安慰剂组9例(HR 0.55,95%CI 0.18-1.65),未达统计学显著。
关键数值与推荐
- 利伐沙班2.5 mg每日两次,在阿司匹林100 mg(全部)或双联抗血小板治疗基础上加用。
- 主要终点为急性肢体缺血、血管原因大截肢、心肌梗死、缺血性卒中及心血管死亡的复合终点。
- 主要安全性结局为TIMI量表定义的大出血。
临床怎么用
- 作者认为有症状外周动脉疾病患者下肢旁路术后应考虑使用利伐沙班,以减少心、肢体和脑的缺血并发症。
局限性
- 旁路手术患者中大出血事件数低(利伐沙班5例 vs 安慰剂9例),未具备检验统计学显著性的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with peripheral artery disease (PAD) requiring lower extremity revascularization (LER) have a high risk of adverse limb and cardiovascular events. The results from the VOYAGER PAD (efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with symptomatic peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities) trial have demonstrated that rivaroxaban significantly reduced this risk with an overall favorable net benefit for patients undergoing surgical revascularization. However, the efficacy and safety for those treated by surgical bypass, including stratification by bypass conduit (venous or prosthetic), has not yet been described. METHODS: In the VOYAGER PAD trial, patients who had undergone surgical and endovascular infrainguinal LER to treat PAD were randomized to rivaroxaban 2.5 mg twice daily or placebo on top of background antiplatelet therapy (aspirin 100 mg to be used in all and clopidogrel in some at the treating physician's discretion) and followed up for a median of 28 months. The primary end point was a composite of acute limb ischemia, major amputation of vascular etiology, myocardial infarction, ischemic stroke, and cardiovascular death. The principal safety outcome was major bleeding using the TIMI (thrombolysis in myocardial infarction) scale. The index procedure details, including conduit type (venous vs prosthetic), were collected at baseline. RESULTS: Among 6564 randomized patients, 2185 (33%) had undergone surgical LER. Of these 2185 patients, surgical bypass had been performed for 1448 (66%), using a prosthetic conduit for 773 patients (53%) and venous conduit for 646 patients (45%). Adjusting for the baseline differences and anatomic factors, the risk of unplanned limb revascularization in the placebo arm was 2.5-fold higher for those receiving a prosthetic conduit vs a venous conduit (adjusted hazard ratio [HR], 2.53; 95% confidence interval [CI], 1.65-3.90; P < .001), and the risk of acute limb ischemia was three times greater (adjusted HR, 3.07; 95% CI, 1.84-5.11; P < .001). The use of rivaroxaban reduced the primary outcome for the patients treated with bypass surgery (HR, 0.78; 95% CI, 0.62-0.98), with consistent benefits for those receiving venous (HR, 0.66; 95% CI, 0.49-0.96) and prosthetic (HR, 0.87; 95% CI, 0.66-1.15) conduits (Pinteraction = .254). In the overall trial, major bleeding using the TIMI scale was increased with rivaroxaban. However, the numbers for those treated with bypass surgery were low (five with rivaroxaban vs nine with placebo; HR, 0.55; 95% CI, 0.18-1.65) and not powered to show statistical significance. CONCLUSIONS: Surgical bypass with a prosthetic conduit was associated with significantly higher rates of major adverse limb events relative to venous conduits even after adjustment for patient and anatomic characteristics. Adding rivaroxaban 2.5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type. Rivaroxaban should be considered after lower extremity bypass for symptomatic PAD to reduce ischemic complications of the heart, limb, and brain.
引用
- Govsyeyev N, Nehler M, Conte MS, et al. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2022. PMID: 36470531. doi:10.1016/j.jvs.2022.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。